Name: Primary Peritoneal Cancer Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3390
Price: 4350 USD
Availability: InStock

Primary Peritoneal Cancer Therapeutics Market Size Share Forecast-2030

Primary Peritoneal Cancer Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Primary Peritoneal Cancer Therapeutics Market is segmented By Treatment Type (Targeted Therapy, Chemotherapy, Surgery, Radiation therapy, Hormone Therapy), By End-users (Hospitals, Surgical Centers, Cancer research institutes, Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The Global Primary Peritoneal Cancer Therapeutics Market is expected to grow at a&nbsp;<a href="https://www.datamintelligence.com/download-sample/primary-peritoneal-cancer-therapeutics-market">CAGR</a>&nbsp;during the forecasting period (2022-2029).
</blockquote>

Primary peritoneal cancer (PPC) is a rare type of cancer. It starts in the thin layer of tissue lining the inside of the abdomen. This tissue lining is called the peritoneum. PPC cells are the same as the most common type of ovarian cancer cells because the lining of the abdomen and the surface of the ovary come from the same tissue where embryos develop in the womb.&nbsp; Most cancers are caused by many different factors working together.&nbsp; A minimal number of PPCs may be linked to the inherited faulty genes BRCA 1 and BRCA 2. These are the same genes that increase the risk of ovarian cancer and breast cancer. PPC mainly affects women. It&#39;s very rare in men. Most people are diagnosed above the age of 60. American research suggests that around 10 out of 100 (around 10%) of all women with ovarian, fallopian and peritoneal serous cancers have PPC. The symptoms of PPC include a swollen tummy (abdomen), abdominal pain, constipation or diarrhea, feeling or being sick, feeling bloated, loss of appetite. The treatment for PPC is the same as for advanced epithelial ovarian cancer: surgery, chemotherapy, and radiotherapy. The market is expected to drive in the future due to the high prevalence rate of ovarian cancers, metastatic gastric, intestinal cancers.

<h2>Market Dynamics</h2>

The global Primary Peritoneal Cancer Therapeutics market growth is driven by the rising number of reported incidences of peritoneal cancer due to increased awareness,&nbsp; number of patients suffering from metastatic gastric, intestinal, and ovarian cancers is expected to increase the incidences of peritoneal cancer, which would lead to an increase in the demand for primary peritoneal cancer therapeutics and also the growing demand for a multidisciplinary treatment regime in closed care are likely to boost the growth of the primary peritoneal cancer therapeutics market.

Increasing incidenece of metastatic gastric, intestinal, and ovarian cancers are expected to increase the incidences of peritoneal cancer.

According to the National Cancer Institute NIH, in 2018, an estimated 235,081 women were living with ovarian cancer in the United States and 2021, it is estimated that there will be 21,410 new cases of ovarian cancer. Out of the whole diagnosed population, 15-20% cases have led to peritoneal metastases. In 2021, it is estimated that 26,560 new cases of gastric cancer are diagnosed. Patients who have gastric cancer have a higher chance (30%) of developing peritoneal cancer at some point in their disease. It is sometimes left untreated, as it cannot be detected by radiological imaging. This can also be one of the main reasons for lower reported incidences of peritoneal cancer, and hence, it is considered a very rare form of cancer.&nbsp;

Major side effects of Surgery and Chemotherapy is likely to hinder the market growth.

Surgery is usually the primary step in treating PPC. Some complications and side effects are Nausea and vomiting, Infection, fever, Wound problem, Fullness due to fluid in the abdomen, Shortness of breath due to fluid around the lungs, Anemia, Swelling caused by lymphedema, usually in the legs or arms, Blood clots, Difficulty urinating or constipation.

Each patient responds to the chemo differently. Some patients may have very few side effects, while others experience several. They include loss of appetite, mouth sores, increased chance of infection, bleeding or bruising easily, hair loss.&nbsp; These are one of the major factors restricting the market growth.

<h2>COVID-19 Impact Analysis</h2>

The COVID-19 pandemic has negatively impacted healthcare systems globally and on the vulvar Cancer market. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.

<h2>Segment Analysis</h2>

Based on Treatment Type, the global Primary Peritoneal Cancer Therapeutics market is segmented into Surgery, Targeted therapy, Hormone therapy, Chemotherapy, Radiation therapy.

There are two treatment methods available for peritoneal cancer patients, including treatment with palliative intent and curative intent. The first option involves treating palliative intent to reduce the pain, surgical intervention to resolve bowel obstruction, and treatment with systemic chemotherapy. The second treatment method with curative intent involves multidisciplinary action on peritoneal cancer with systemic chemotherapy, hyperthermic intraperitoneal chemotherapy, and tumor removal surgery.&nbsp;

The targeted therapy segment, along with chemotherapy, is expected to boost the growth of the primary peritoneal cancer therapeutics market.&nbsp;

Chemotherapy cancer treatment uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. One type of regional chemotherapy used to treat peritoneal cancer is Intraperitoneal (IP) chemotherapy. In this, anticancer drugs like carboplatin, paclitaxel are directly carried into the peritoneal cavity (the space that contains the abdominal organs) through a thin tube, and Hyperthermic intraperitoneal chemotherapy (HIPEC) treatment is used during surgery that is being studied for advanced ovarian cancer. After the surgeon has removed as much tumor tissue as possible, warmed chemotherapy is sent directly into the peritoneal cavity.

Targeted therapy is another type of treatment that uses drugs or other substances to identify and attack specific cancer cells. For instance, Poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) are targeted therapy drugs that block DNA repair and cause cancer cells to die. Drugs like Olaparib, rucaparib and niraparib are PARP inhibitors that may be used to treat peritoneal cancers. Olaparib and Rucaparib may also be used as maintenance therapy to treat Reoccurred ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

For instance, Elevar Therapeutics and Tanner Pharma Group Announced the Global Named Patient Program to Provide Access to Apealea&reg; (micellular paclitaxel) on July 27, 2020.

Based on End-User, the global Primary Peritoneal Cancer Therapeutics market is segmented into Hospitals, Cancer Research centers, Surgical centers, others.

Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously and surgery is done under supervision of medical practioners at these locations.

<h2>Geographical Analysis</h2>

North America served the largest share of the market due to the increasing prevalence of Peritoneal Cancer cases. According to the American Cancer Society, in 2021, it is estimated that there will be 21,410 new cases of ovarian cancer. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and targeted therapy methods, the total availability of advanced diagnostic tools, and many companies are developing oncology products. For instance, GSK undergoing Phase III clinical trials (NCT04679064) of GSK3985771 &dagger;niraparib Zejula- Advanced Ovarian cancer 1L maintenance combo with dostarlimab (Poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor).

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Takeda Pharmaceuticals conducted A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Niraparib in Japanese Patients with Advanced, Relapsed, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received 3 or 4 Previous Chemotherapy Regimens.

<h2>Competitive Landscape&nbsp;</h2>

The Global Primary Peritoneal Cancer Therapeutics Market is quite competitive with some key competitors like Eli Lilly and company, Amgen, GlaxoSmithKline Plc, Hoffmann-La Roche, Novartis Pharmaceuticals Corporation, Genentech USA, Astra Zeneca, Sanofi Aventis, Janssen Pharmaceuticals, Inc and Pfizer. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors.&nbsp;

For instance, according to clinicaltrials.gov; Novartis Pharmaceuticals in Collaboration with GlaxoSmithKline- A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First-Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Hoffmann-La Roche Ltd

Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to drive personalized healthcare further. Two-thirds of our Research and Development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009.

Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases and others.

Key developments:

Hoffmann-La Roche-An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab (Avastin) in the Front-Line Management of Advanced/Metastatic Primary Peritoneal Cancer in Real-life Clinical Practice.

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the Primary Peritoneal Cancer Therapeutics Market segmentation by Treatment type, End-users, and region highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in Primary Peritoneal Cancer Therapeutics Market by analyzing trends and co-development deals.&nbsp;</li>
	<li>Excel data sheet with thousands of data points of Primary Peritoneal Cancer Therapeutics Market - level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.&nbsp;</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global Primary Peritoneal Cancer Therapeutics Market report would provide an access to an approx. 53 market data table, 45 figures and 180 pages.&nbsp;

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/cancer-anorexia-cachexia-syndrome-drug-market">Cancer Anorexia-Cachexia Syndrome Drug Market</a>

<a href="https://www.datamintelligence.com/research-report/cancer-vaccines-market">Cancer Vaccines Market</a>

<a href="https://www.datamintelligence.com/research-report/cancer-tumor-profiling-market">Cancer Tumor Profiling Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Market Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Market Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Market snippet by Treatment Type</li>
		<li>Market Snippet by End-users</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing prevalence of metastatic gastric, intestinal, and ovarian cancers worldwide</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>Side effects associated with the surgery and chemotherapy</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Treatment type</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type</li>
		<li>Market Attractiveness Index, By Treatment type
		<ol>
			<li>Targeted Therapy*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Chemotherapy</li>
			<li>Surgery</li>
			<li>Radiation therapy</li>
			<li>Hormone Therapy</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End-users</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users segment</li>
		<li>Market Attractiveness Index, By End-users Segment
		<ol>
			<li>Hospitals*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Surgical Centers</li>
			<li>Cancer research institutes&nbsp;</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction&nbsp;</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region</li>
		<li>Market Attractiveness Index, By Region</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Global Primary Peritoneal Cancer Therapeutics Market - Company Profiles</h3>

	<ol>
		<li>Hoffmann-La Roche Ltd*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Eli Lilly and company,&nbsp;</li>
		<li>Amgen,&nbsp;</li>
		<li>GlaxoSmithKline Plc,&nbsp;</li>
		<li>Novartis Pharmaceuticals Corporation,&nbsp;</li>
		<li>Genentech USA,&nbsp;</li>
		<li>Astra Zeneca,&nbsp;</li>
		<li>Sanofi Aventis,&nbsp;</li>
		<li>Janssen Pharmaceuticals, Inc&nbsp;</li>
		<li>Pfizer Inc(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Premium Insights</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">DataM Intelligence</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 1 Global Primary Peritoneal Cancer Therapeutics Market Value, By Treatment Type, 2021,2025 &amp; 2029 ($ Million)

Table 2 Global Primary Peritoneal Cancer Therapeutics Market Value, By End-Users, 2021,2025 &amp; 2029 ($ Million)

Table 3 Global Primary Peritoneal Cancer Therapeutics Market Value, By Region, 2021,2025 &amp; 2029 ($ Million)

Table 4 Global Primary Peritoneal Cancer Therapeutics Market Value, By Treatment Type, 2021,2025 &amp; 2029 ($ Million)

Table 5 Global Primary Peritoneal Cancer Therapeutics Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 6 Global Primary Peritoneal Cancer Therapeutics Market Value, By End-Users, 2021,2025 &amp; 2029 ($ Million)

Table 7 Global Primary Peritoneal Cancer Therapeutics Market Value, By End-Users, 2018-2029 ($ Million)

Table 8 Global Primary Peritoneal Cancer Therapeutics Market Value, By Region, 2021,2025 &amp; 2029 ($ Million)

Table 9 Global Primary Peritoneal Cancer Therapeutics Market Value, By Region, 2018-2029 ($ Million)

Table 10 North America Primary Peritoneal Cancer Therapeutics Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 11 North America Primary Peritoneal Cancer Therapeutics Market Value, By End-Users, 2018-2029 ($ Million)

Table 12 North America Primary Peritoneal Cancer Therapeutics Market Value, By Country, 2018-2029 ($ Million)

Table 13 South America Primary Peritoneal Cancer Therapeutics Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 14 South America Primary Peritoneal Cancer Therapeutics Market Value, By End-Users, 2018-2029 ($ Million)

Table 15 South America Primary Peritoneal Cancer Therapeutics Market Value, By Country, 2018-2029 ($ Million)

Table 16 Europe Primary Peritoneal Cancer Therapeutics Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 17 Europe Primary Peritoneal Cancer Therapeutics Market Value, By End-Users, 2018-2029 ($ Million)

Table 18 Europe Primary Peritoneal Cancer Therapeutics Market Value, By Country, 2018-2029 ($ Million)

Table 19 Asia-Pacific Primary Peritoneal Cancer Therapeutics Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 20 Asia-Pacific Primary Peritoneal Cancer Therapeutics Market Value, By End-Users, 2018-2029 ($ Million)

Table 21 Asia-Pacific Primary Peritoneal Cancer Therapeutics Market Value, By Country, 2018-2029 ($ Million)

Table 22 Middle East &amp; Africa Primary Peritoneal Cancer Therapeutics Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 23 Middle East &amp; Africa Primary Peritoneal Cancer Therapeutics Market Value, By End-Users, 2018-2029 ($ Million)

Table 24 Hoffmann-La Roche Ltd: Overview

Table 25 Hoffmann-La Roche Ltd: Product Portfolio

Table 26 Hoffmann-La Roche Ltd: Key Developments

Table 27 Eli Lilly and Company: Overview

Table 28 Eli Lilly and Company: Product Portfolio

Table 29 Eli Lilly and Company: Key Developments

Table 30 GlaxoSmithKline Plc: Overview

Table 31 GlaxoSmithKline Plc: Product Portfolio

Table 32 GlaxoSmithKline Plc: Key Developments

Table 33 Amgen: Overview

Table 34 Amgen: Product Portfolio

Table 35 Amgen: Key Developments

Table 36 Pfizer Inc: Overview

Table 37 Pfizer Inc: Product Portfolio

Table 38 Pfizer Inc: Key Developments

Table 39 Novartis Pharmaceuticals Corporation: Overview

Table 40 Novartis Pharmaceuticals Corporation: Product Portfolio

Table 41 Novartis Pharmaceuticals Corporation: Key Developments

Table 42 Genentech USA: Overview

Table 43 Genentech USA: Product Portfolio

Table 44 Genentech USA: Key Developments

Table 45 Astra Zeneca: Overview

Table 46 Astra Zeneca: Product Portfolio

Table 47 Astra Zeneca: Key Developments

Table 48 Sanofi Aventis: Overview

Table 49 Sanofi Aventis: Product Portfolio

Table 50 Sanofi Aventis: Key Developments

Table 51 Janssen Pharmaceuticals, Inc: Overview

Table 52 Janssen Pharmaceuticals, Inc: Product Portfolio

Table 53 Janssen Pharmaceuticals, Inc: Key Developments

&nbsp;

List of Figures

Figure 1 Global Primary Peritoneal Cancer Therapeutics Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 2 Global Primary Peritoneal Cancer Therapeutics Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 3 Global Primary Peritoneal Cancer Therapeutics Market Share, By Region, 2021 &amp; 2029 (%)

Figure 4 Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 5 Global Primary Peritoneal Cancer Therapeutics Market Y-o-Y Growth, By Treatment Type, 2021-2029 (%)

Figure 6 Targeted Therapy: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 7 Chemotherapy: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 8 Surgery: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 9 Radiation Therapy: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 10 Hormone therapy: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 11 Global Primary Peritoneal Cancer Therapeutics Market Y-o-Y Growth, By End-Users, 2021-2029 (%)

Figure 12 Hospitals: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 13 Cancer research institutes: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 14 Surgical Centers: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 15 Others: Global Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 16 Global Primary Peritoneal Cancer Therapeutics Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 17 North America Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 18 North America Primary Peritoneal Cancer Therapeutics Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 19 North America Primary Peritoneal Cancer Therapeutics Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 20 North America Primary Peritoneal Cancer Therapeutics Market Share, By Country, 2021 &amp; 2029 (%)

Figure 21 South America Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 22 South America Primary Peritoneal Cancer Therapeutics Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 23 South America Primary Peritoneal Cancer Therapeutics Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 24 South America Primary Peritoneal Cancer Therapeutics Market Share, By Country, 2021 &amp; 2029 (%)

Figure 25 Europe Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 26 Europe Primary Peritoneal Cancer Therapeutics Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 27 Europe Primary Peritoneal Cancer Therapeutics Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 28 Europe Primary Peritoneal Cancer Therapeutics Market Share, By Country, 2021 &amp; 2029 (%)

Figure 29 Asia-Pacific Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 30 Asia-Pacific Primary Peritoneal Cancer Therapeutics Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 31 Asia-Pacific Primary Peritoneal Cancer Therapeutics Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 32 Asia-Pacific Primary Peritoneal Cancer Therapeutics Market Share, By Country, 2021 &amp; 2029 (%)

Figure 33 Middle East &amp; Africa Primary Peritoneal Cancer Therapeutics Market Value, 2018-2029 ($ Million)

Figure 34 Middle East &amp; Africa Primary Peritoneal Cancer Therapeutics Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 35 Middle East &amp; Africa Primary Peritoneal Cancer Therapeutics Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 36 Hoffmann-La Roche Ltd: Financials

Figure 37 Eli Lilly and company: Financials

Figure 38 GlaxoSmithKline Plc: Financials

Figure 39 Amgen: Financials

Figure 40 Pfizer Inc: Financials

Figure 41 Novartis Pharmaceuticals Corporation: Financials

Figure 42 Genentech USA: Financials

Figure 43 Astra Zeneca: Financials

Figure 44 Sanofi Aventis: Financials

Figure 45 Janssen Pharmaceuticals, Inc: Financials